Adding ezetimibe to intensive statin therapy following acute coronary syndrome provides greater benefits to elderly patients than those in lower age groups, a US study has found.

In a secondary analysis of the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) study, researchers compared the effects of simvastatin-ezetimibe combination therapy versus simvastatin alone by age group in more than 18,000 participants (mean age 64).